PURPOSE: For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA nadir of more than 0.2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM). PATIENTS AND METHODS: The study cohort comprised 747 men with rising PSA and negative bone scan after surgery (n = 486) or radiation therapy (n = 261) who were treated with AST. Cox regression was used to evaluate whether a significant association existed between the PSA nadir level after 8 months of AST and the time to PCSM, controlling for treatment and known prognostic factors. RESULTS: The post-AST PSA nadir (pCox < .0001), the pre-AST PSA doubling time (DT) (pCox = .002), PSA level (P = .0001), and Gleason eight to 10 cancers (pCox = .01) were significantly associated with time to PCSM. The adjusted hazard ratio for PCSM was 20 (95% CI, 7 to 61; pCox < .0001), for men with a PSA nadir of more than 0.2 ng/mL as compared with all others. A PSA DT of less than 3 months was observed in 30% (224 of 747) of the study cohort. Of the 28 observed prostate cancer deaths, 21 (75%) occurred in men whose PSA nadir was more than 0.2 ng/mL and who had a PSA DT of less than 3 months. CONCLUSION: A PSA nadir of more than 0.2 ng/mL after 8 months of AST given for postoperative or postradiation PSA failure is significantly associated with PCSM and is clinically significant because it accounted for 75% of the cancer deaths observed in this study.
PURPOSE: For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA nadir of more than 0.2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM). PATIENTS AND METHODS: The study cohort comprised 747 men with rising PSA and negative bone scan after surgery (n = 486) or radiation therapy (n = 261) who were treated with AST. Cox regression was used to evaluate whether a significant association existed between the PSA nadir level after 8 months of AST and the time to PCSM, controlling for treatment and known prognostic factors. RESULTS: The post-AST PSA nadir (pCox < .0001), the pre-AST PSA doubling time (DT) (pCox = .002), PSA level (P = .0001), and Gleason eight to 10 cancers (pCox = .01) were significantly associated with time to PCSM. The adjusted hazard ratio for PCSM was 20 (95% CI, 7 to 61; pCox < .0001), for men with a PSA nadir of more than 0.2 ng/mL as compared with all others. A PSADT of less than 3 months was observed in 30% (224 of 747) of the study cohort. Of the 28 observed prostate cancer deaths, 21 (75%) occurred in men whose PSA nadir was more than 0.2 ng/mL and who had a PSADT of less than 3 months. CONCLUSION: A PSA nadir of more than 0.2 ng/mL after 8 months of AST given for postoperative or postradiation PSA failure is significantly associated with PCSM and is clinically significant because it accounted for 75% of the cancer deaths observed in this study.
Authors: Anton Ponholzer; Franz Stoiber; Wolfgang Loidl; Michael Rauchenwald; Paul Schramek; Stephan Madersbacher Journal: Wien Med Wochenschr Date: 2009
Authors: Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Dana Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Christopher J Keto; William J Aronson; Martha K Terris; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Eur Urol Date: 2012-12-06 Impact factor: 20.096
Authors: Sudipto Das; Yoonsoo Hahn; Dawn A Walker; Satoshi Nagata; Mark C Willingham; Donna M Peehl; Tapan K Bera; Byungkook Lee; Ira Pastan Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: David J D'Ambrosio; Karen Ruth; Eric M Horwitz; Robert G Uzzo; Alan Pollack; Mark K Buyyounouski Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: Philip M Arlen; Fernando Bianco; William L Dahut; Anthony D'Amico; William D Figg; Stephen J Freedland; James L Gulley; Philip W Kantoff; Michael W Kattan; Andrew Lee; Meredith M Regan; Oliver Sartor Journal: J Urol Date: 2008-04-18 Impact factor: 7.450